

# ForPatients

by Roche

Non-Small Cell Lung Cancer (NSCLC)

## A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

**Trial Status**  
Completed

**Trial Runs In**  
19 Countries

**Trial Identifier**  
NCT02031458 2013-003330-32  
GO28754

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is, in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02031458 2013-003330-32 GO28754**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---